Literature DB >> 30363682

Resection for hepatocellular cancer: overpassing old barriers.

Francesco Giovanardi1, Quirino Lai1, Alessandra Bertacco2, Alessandro Vitale2.   

Abstract

Several recent studies have shown that the selection limits commonly used for patients with hepatocellular cancer (HCC) potentially requiring a liver resection (LR) are too restrictive. The present review aims at investigating the studies showing that LR is no longer a treatment suitable only for highly selected patients, but also for patients selectively presenting one-to-more negative factors. Several specific variables have been investigated, none of them showing to be an absolute contraindication for LR: age; single vs. multiple diseases; the dimension of the nodule; hyperbilirubinemia; clinically relevant portal hypertension; Child-Pugh status; macrovascular invasion. As a consequence, LR for the treatment of HCC-on-cirrhosis is a safe and effective procedure not only in "ideal cases", but also for selected patients presenting risk factors. The presence of only one of these factors does not represent an absolute contraindication for LR. On the opposite, the contemporaneous presence of risk factors should contraindicate the procedure. Further studies investigating the "borderline" cases are required, mainly looking at the possible decisive role of laparoscopy in this setting.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer (BCLC); Portal hypertension (PHT); liver failure; mini-invasive surgery; model for end-stage liver disease (MELD)

Year:  2018        PMID: 30363682      PMCID: PMC6182022          DOI: 10.21037/tgh.2018.09.13

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  76 in total

1.  Hepatic resection for huge (>15 cm) multinodular HCC with macrovascular invasion.

Authors:  Jiwei Huang; Roberto Hernandez-Alejandro; Kristopher P Croome; Yong Zeng; Hong Wu; Zheyu Chen
Journal:  J Surg Res       Date:  2012-05-15       Impact factor: 2.192

2.  Outcomes of hepatic resection for huge hepatocellular carcinoma (≥ 10 cm in diameter).

Authors:  Yo-ichi Yamashita; Akinobu Taketomi; Ken Shirabe; Shinichi Aishima; Eiji Tsuijita; Kazutoyo Morita; Hiroto Kayashima; Yoshihiko Maehara
Journal:  J Surg Oncol       Date:  2011-04-04       Impact factor: 3.454

Review 3.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

4.  Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis.

Authors:  Alexander Zipprich; Oliver Kuss; Sebastian Rogowski; Gerhard Kleber; Erich Lotterer; Thomas Seufferlein; Wolfgang E Fleig; Matthias M Dollinger
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

5.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

6.  Liver resection in hepatitis B related-hepatocellular carcinoma: clinical outcomes and safety in elderly patients.

Authors:  Hai-Qing Wang; Jian Yang; Lu-Nan Yan; Xiao-Wu Zhang; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

7.  The international position on laparoscopic liver surgery: The Louisville Statement, 2008.

Authors:  Joseph F Buell; Daniel Cherqui; David A Geller; Nicholas O'Rourke; David Iannitti; Ibrahim Dagher; Alan J Koffron; Mark Thomas; Brice Gayet; Ho Seong Han; Go Wakabayashi; Giulio Belli; Hironori Kaneko; Chen-Guo Ker; Olivier Scatton; Alexis Laurent; Eddie K Abdalla; Prosanto Chaudhury; Erik Dutson; Clark Gamblin; Michael D'Angelica; David Nagorney; Giuliano Testa; Daniel Labow; Derrik Manas; Ronnie T Poon; Heidi Nelson; Robert Martin; Bryan Clary; Wright C Pinson; John Martinie; Jean-Nicolas Vauthey; Robert Goldstein; Sasan Roayaie; David Barlet; Joseph Espat; Michael Abecassis; Myrddin Rees; Yuman Fong; Kelly M McMasters; Christoph Broelsch; Ron Busuttil; Jacques Belghiti; Steven Strasberg; Ravi S Chari
Journal:  Ann Surg       Date:  2009-11       Impact factor: 12.969

8.  Comparison of short-term outcomes in laparoscopic vs open hepatectomy.

Authors:  Cara Franken; Briana Lau; Krishna Putchakayala; L Andrew DiFronzo
Journal:  JAMA Surg       Date:  2014-09       Impact factor: 14.766

9.  Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.

Authors:  Jian-Hong Zhong; Bang-De Xiang; Wen-Feng Gong; Yang Ke; Qin-Guo Mo; Liang Ma; Xing Liu; Le-Qun Li
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

10.  Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

Authors:  Sabrina Kermiche-Rahali; Aude Di Fiore; Fanny Drieux; Frédéric Di Fiore; Arnaud François; Michel Scotté
Journal:  World J Surg Oncol       Date:  2013-08-02       Impact factor: 2.754

View more
  1 in total

1.  Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients.

Authors:  Chang-Zhi Chen; Jian-Hong Zhong; Ya-Peng Qi; Jie Zhang; Tao Huang; Liang Ma; Le-Qun Li; Tao Peng; Bang-De Xiang
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.